Novo flunks kidney disease trial, again linking obesity prospect to neuropsychiatric side effects - Fierce Biotech
Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that left investors underwhelmed, the Danish drugmaker has reported…
Comments